Navigation Links
Insmed Announces Fourth Quarter and Full-Year 2010 Financial Results
Date:3/10/2011

RICHMOND, Va., March 10, 2011 /PRNewswire/ -- Insmed Inc. (Nasdaq CM: INSMD), a biopharmaceutical company, today reported results for the fourth quarter and full-year ended December 31, 2010.

Key Recent Highlights:

  • Filed Investigational New Drug (IND) Application in February 2011 with the FDA to begin a phase 3 clinical trial for ARIKACE™ (liposomal amikacin for inhalation) in non-TB Mycobacteria (NTM) lung infections.
  • Successfully concluded 72 week phase 2b open-label study for ARIKACE for pseudomonas lung infections in cystic fibrosis (CF) patients.
  • Received positive opinion from European Medicines Agency (EMA) on Company's Pediatric Investigation Plan for ARIKACE in the CF indication.
  • Gained shareholder approval for conversion of preferred stock into common stock and 1:10 reverse stock split.

  • "Following the closure of our transformative business combination in December 2010, we have been aggressively moving forward with the development plan for ARIKACE, our phase 3 compound for pseudomonas lung infections for CF patients, and NTM lung infections," said Timothy Whitten, Insmed's President & CEO.  "We are well underway with the initial preparations and necessary work around these trials and continue to expect to begin accruing patients to the phase 3 trials in both indications in the second half of 2011, with results expected in the first half of 2013."

    Financial ResultsOn March 1, 2011, at a special meeting, our shareholders approved a one for 10 reverse stock split of our common stock, which became effective at 5:00 pm EST on March 2, 2011.  This reverse stock split is reflected in the shares outstanding and earnings per share calculations below.  

    Revenues for the fourth quarter ended December 31, 2010 were $1.3 million, as compared to $2.5 million for the corresponding period in 2009.  The $1.2 million decrease resulted from $0.6 million in lower cost r
    '/>"/>

    SOURCE Insmed Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Insmed to Host Second Quarter 2009 Conference Call
    2. Insmed Announces Addition to the Russell 3000(R) Index
    3. Insmed Announces Results of IPLEX(TM) Phase II Trial in Myotonic Muscular Dystrophy
    4. Insmed CEO Resigns Due to Health Concerns
    5. Insmed Announces First Quarter 2009 Financial Results
    6. Insmed Regains NASDAQ Compliance
    7. Insmed to Host First Quarter 2009 Conference Call
    8. Insmed Announces Agreement With IDIS to Manage Expanded Access Programs for IPLEX(TM)
    9. Insmed Announces That NASDAQ Further Extends Temporary Suspension of Minimum Bid Closing Price Rule
    10. Insmed Announces Fourth Quarter and Full-Year 2008 Financial Results
    11. Insmed to Host Fourth Quarter and Full-Year 2008 Conference Call
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:9/1/2015)... , Sept. 1, 2015 The Dohmen ... Floyd , Ph.D., MBA as Chief Science Officer ... this newly created role, Dr. Floyd will lead ... a portfolio of pre-commercial and post approval outsourced ... and medical communications.  Dr. Floyd brings decades of ...
    (Date:9/1/2015)... , ... September 01, 2015 , ... ... Director of Business Development, Asia Pacific. In this newly-created position, Gibbs will lead ... and use of iLab’s suite of tools. This entails not only introducing iLab ...
    (Date:9/1/2015)... Shire plc (LSE: SHP, NASDAQ: SHPG ) ... Board of Directors as a Non-Executive Director. Sara will also ... of the Shire Board. Both appointments will be effective as ... Chairman, President and Chief Executive Officer of Dun & Bradstreet, ... at D&B, she helped drive the transformation of the company ...
    (Date:8/31/2015)... Aug. 31, 2015 MabVax Therapeutics Holdings, Inc. ... that the Company,s lead antibody, HuMab 5B1, will be ... presentations during the upcoming World Molecular Imaging Congress (WMIC) ... 2-5, 2015. Researchers from the Department of Radiology at ... on the use of MabVax,s lead antibody as a ...
    Breaking Biology Technology:Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 2Dohmen Life Science Services Appoints Eric Floyd, Ph.D. as Chief Science Officer 3iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 2iLab Solutions Hires Gerard Gibbs, Director of Business Development, Asia Pacific 3Shire Appoints Sara Mathew to Board of Directors 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 2MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 3MabVax Therapeutics HuMab 5B1 Antibody Is Highlighted at Upcoming World Molecular Imaging Congress in Five Separate Presentations 4
    ... Jennerex, Inc., a clinical-stage biotherapeutics company focused ... targeted oncolytic products for cancer, today announced the ... with aggregate gross proceeds of approximately $8.6 million. ... be used to advance the Company,s oncology product ...
    ... at the National Institute of Standards and Technology (NIST) ... world,s darkest material‑a forest of carbon nanotubes that reflects ... the infrared spectrum., NIST will use the new ultra-dark ... Letters ,* to make precision laser power measurements for ...
    ... 18 Regenicin, Inc. (OTC Bulletin Board: ... that it has completed an initial $3.25 million funding ... license to know-how technology controlled by Lonza Walkersville ("Lonza ... Ltd. (SIX: LONN), one of the world,s leading suppliers ...
    Cached Biology Technology:Jennerex Completes Fully Subscribed Private Placement for Aggregate Gross Proceeds of $8.6 Million 2Extreme darkness: Carbon nanotube forest covers NIST's ultra-dark detector 2Regenicin Completes Acquisition of Worldwide Exclusive Know-How Technology License from Lonza Walkersville 2
    (Date:8/20/2015)... Aug. 20, 2015 The wearable technology ... are active and healthy. However, wearable technology has ... environment to help improve diagnostic capabilities and therapeutic ... the Wearable Technologies Conference 2015 , where ... for wearables in healthcare.    "Over ...
    (Date:8/18/2015)... Research and Markets ( http://www.researchandmarkets.com/research/9dmm6l/global_biometric ) ... Biometric Authentication & Identification Market: Focus On Modality, ... report to their offering. ... is expected to grow at an estimated CAGR ... over $25 billion (approximately) by 2020 as per ...
    (Date:8/12/2015)... SAN JOSE, Calif. , Aug. 12, 2015 ... leading developer of human interface solutions, today announced ... the recently announced Match-in-Sensor solution, have officially been ... (FIDO) Alliance. As part of the certification, Synaptics, ... the FIDO 1.0 Universal Authentication Framework (UAF) standard ...
    Breaking Biology News(10 mins):Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 2Leaf Healthcare Releases Video from Wearable Technology Conference on New Applications for Wearables in the Hospital Environment 3Global Biometric Authentication & Identification Market 2015: Focus On Modality, Motility & Application - Estimation & Forecasts to 2020 for the $25 Billion Industry 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 2Synaptics Announces FIDO Certification of Natural ID Fingerprint Solutions 3
    ... for spiders, it can be a matter of life or ... potentially cannibalistic females that he is a suitable mate and ... Cincinnati shows that male wolf spiders are "leaving" little to ... mate. To improve the chances of the right message ...
    ... A new company has been launched to commercialise ... Strathclyde in Glasgow, for tackling bacterial infection and ... Phage Limited has been established to develop products ... prevention of infection and bacterial contamination in medicine, ...
    ... standard intestinal examination for diagnosing and monitoring Crohn,s disease. It ... with a camera is passed into the large intestine. MRI ... the course of the disease and how it is responding ... the academic world to develop an objective, quantitative method for ...
    Cached Biology News:Spiders adjust courtship signals for maximum effect 2Spiders adjust courtship signals for maximum effect 3Spin-out to apply new technology for tackling infection 2Spin-out to apply new technology for tackling infection 3EU grant for better monitoring of Crohn's disease using MRI 2EU grant for better monitoring of Crohn's disease using MRI 3
    BD Falcon microtest assay plate. 1536 well 12l, black, flat-bottom PS. Polystyrene, nonsterile, no lid. (15/sp, 60/ca) Packaging: 15 / pack, 60 / case ...
    ... Chamber lid allows easy gel observation and provides ... easy set up between power supply and migration ... if the lid is removed at the migration ... Remote control can be easily operated in ...
    ... have low background fluorescence, minimal light ... (or medium binding) polystyrene surface is ... through passive interactions,• Is suitable ... molecules, such as antibodies, that have ...
    ... Model 1575 immunowash microplate washer 100-240 V, ... have flat-, U-, or V-bottom wells. The ... and vertical needle positions to an accuracy ... aspiration, and overflow washing. It can store ...
    Biology Products: